KT101

**KT101** is an investigational preclinical **protein drug** being developed by **Keren Therapeutics** for **sarcopenia** and potentially other age-related muscle-wasting or neurologic disorders. Publicly accessible pipeline sources consistently identify KT101 as Keren's lead program and classify it as a biologic or protein therapeutic, but they do **not** provide enough high-confidence public detail to define its exact molecular identity, formulation, route, or target biology. Company-profile materials for Keren describe the platform more broadly as leveraging a **naturally occurring peptide hormone** associated with restoration of muscle function, and one publicly indexed company summary links Keren's programs to **osteocalcin biology**; however, I cannot confirm from the available sources that KT101 itself is definitively osteocalcin or a specific osteocalcin-derived product. As a result, KT101 is best described as a **preclinical muscle-function restorative protein therapeutic candidate for sarcopenia with mechanism not yet publicly characterized in sufficient detail**.

Other names

microdose pilocarpineKedalion microdose pilocarpine